Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 2/2016

01.04.2016 | leitlinien für die praxis

Geriatrische Aspekte bei Diabetes mellitus

verfasst von: Joakim Huber, Michael Smeikal, Monika Lechleitner, Peter Fasching

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Es besteht eine hohe Prävalenz an Diabetes mellitus Typ 2 bei über 70-Jährigen in industrialisierten Ländern. Dieser Artikel enthält Empfehlungen für die Diagnose, die Prävention und die Therapieziele in der Behandlung des älteren diabetischen Patienten anhand der aktuellen Evidenzlage.
Literatur
1.
Zurück zum Zitat Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46:182–9. PubMed Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46:182–9. PubMed
2.
Zurück zum Zitat DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61–9. CrossRef DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61–9. CrossRef
3.
Zurück zum Zitat Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000;23:176–80. CrossRefPubMed Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000;23:176–80. CrossRefPubMed
4.
Zurück zum Zitat Hauner H, Kurnaz AA, Haastert B, Groschopp C, Feldhoff KH. Undiagnosed diabetes mellitus and metabolic control assessed by HbA(1c) among residents of nursing homes. Exp Clin Endocrinol Diabetes. 2001;109:326–9. CrossRefPubMed Hauner H, Kurnaz AA, Haastert B, Groschopp C, Feldhoff KH. Undiagnosed diabetes mellitus and metabolic control assessed by HbA(1c) among residents of nursing homes. Exp Clin Endocrinol Diabetes. 2001;109:326–9. CrossRefPubMed
5.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34 Suppl 1:S11–61. CrossRefPubMedCentral American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34 Suppl 1:S11–61. CrossRefPubMedCentral
6.
Zurück zum Zitat American Diabetes Association. (2) classification and diagnosis of diabetes. Diabetes Care. 201 5;38 Suppl 1:S8–16. American Diabetes Association. (2) classification and diagnosis of diabetes. Diabetes Care. 201 5;38 Suppl 1:S8–16.
7.
Zurück zum Zitat Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–7. CrossRefPubMed Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–7. CrossRefPubMed
8.
Zurück zum Zitat Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care. 1998;21:231–5. CrossRefPubMed Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care. 1998;21:231–5. CrossRefPubMed
9.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. CrossRefPubMed
10.
Zurück zum Zitat Jefferis BJ, Whincup PH, Lennon L, Wannamethee SG. Longitudinal associations between changes in physical activity and onset of type 2 diabetes in older British men: the influence of adiposity. Diabetes Care. 2012;35:1876–83. CrossRefPubMedPubMedCentral Jefferis BJ, Whincup PH, Lennon L, Wannamethee SG. Longitudinal associations between changes in physical activity and onset of type 2 diabetes in older British men: the influence of adiposity. Diabetes Care. 2012;35:1876–83. CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–29. CrossRefPubMedPubMedCentral Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–29. CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Meneilly GS, Knip A, Tessier D. Diabetes in the elderly. Can J Diabetes. 2013;37 Suppl 1:S184–90. CrossRefPubMed Meneilly GS, Knip A, Tessier D. Diabetes in the elderly. Can J Diabetes. 2013;37 Suppl 1:S184–90. CrossRefPubMed
13.
Zurück zum Zitat Evans WJ. Protein nutrition, exercise and aging. J Am Coll Nutr. 2004;23:601–9. CrossRef Evans WJ. Protein nutrition, exercise and aging. J Am Coll Nutr. 2004;23:601–9. CrossRef
14.
Zurück zum Zitat Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34:1329–36. CrossRefPubMedPubMedCentral Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34:1329–36. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. CrossRefPubMed Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. CrossRefPubMed
16.
Zurück zum Zitat Tan HH, McAlpine RR, James P, et al. Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care. 2004;27:2797–9. CrossRefPubMed Tan HH, McAlpine RR, James P, et al. Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care. 2004;27:2797–9. CrossRefPubMed
17.
Zurück zum Zitat Zeyfang A, Braun A. [Guidelines „Diabetes mellitus in the elderly“]. MMW Fortschr Med. 2009;151:33–5, 37. PubMed Zeyfang A, Braun A. [Guidelines „Diabetes mellitus in the elderly“]. MMW Fortschr Med. 2009;151:33–5, 37. PubMed
18.
Zurück zum Zitat Zeyfang A, Bahrmann A, Wernecke J. Diabetes mellitus im Alter. Diabetologie. 2014;9:189–95. Zeyfang A, Bahrmann A, Wernecke J. Diabetes mellitus im Alter. Diabetologie. 2014;9:189–95.
19.
Zurück zum Zitat Siegmund T, Schumm-Draeger PM. Therapie mit oralen Antidiabetika und/oder Insulin im höheren Alter? Diabetologe. 2010;6:560–9. CrossRef Siegmund T, Schumm-Draeger PM. Therapie mit oralen Antidiabetika und/oder Insulin im höheren Alter? Diabetologe. 2010;6:560–9. CrossRef
20.
Zurück zum Zitat Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471–5. CrossRefPubMed Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471–5. CrossRefPubMed
21.
Zurück zum Zitat Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000;23:1272–7. CrossRefPubMed Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000;23:1272–7. CrossRefPubMed
22.
Zurück zum Zitat Krop JS, Powe NR, Weller WE, Shaffer TJ, Saudek CD, Anderson GF. Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care. Diabetes Care. 1998;21:747–52. CrossRefPubMed Krop JS, Powe NR, Weller WE, Shaffer TJ, Saudek CD, Anderson GF. Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care. Diabetes Care. 1998;21:747–52. CrossRefPubMed
23.
Zurück zum Zitat Rawlings AM, Sharrett AR, Schneider AL, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 161:785–93. Rawlings AM, Sharrett AR, Schneider AL, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 161:785–93.
24.
Zurück zum Zitat Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42:484–91. CrossRefPubMed Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42:484–91. CrossRefPubMed
25.
Zurück zum Zitat Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105. CrossRefPubMed Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105. CrossRefPubMed
26.
Zurück zum Zitat Katon W, Pedersen HS, Ribe AR, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry. 2015;72:612–9. CrossRefPubMed Katon W, Pedersen HS, Ribe AR, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry. 2015;72:612–9. CrossRefPubMed
27.
Zurück zum Zitat van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 2013;8:e57058. CrossRefPubMedPubMedCentral van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 2013;8:e57058. CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care. 2003;26:2822–8. CrossRefPubMed Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care. 2003;26:2822–8. CrossRefPubMed
29.
Zurück zum Zitat Kimbro LB, Mangione CM, Steers WN, et al. Depression and all-cause mortality in persons with diabetes mellitus: are older adults at higher risk? Results from the translating research into action for diabetes study. J Am Geriatr Soc. 2014;62:1017–22. CrossRefPubMedPubMedCentral Kimbro LB, Mangione CM, Steers WN, et al. Depression and all-cause mortality in persons with diabetes mellitus: are older adults at higher risk? Results from the translating research into action for diabetes study. J Am Geriatr Soc. 2014;62:1017–22. CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006;67:235–40. CrossRefPubMed Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006;67:235–40. CrossRefPubMed
31.
Zurück zum Zitat Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7. CrossRefPubMedPubMedCentral Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7. CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72. CrossRefPubMedPubMedCentral Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72. CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012;35:787–93. CrossRefPubMedPubMedCentral Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012;35:787–93. CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. CrossRefPubMed Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. CrossRefPubMed
35.
Zurück zum Zitat Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98. CrossRefPubMed Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98. CrossRefPubMed
36.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72. CrossRefPubMed Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72. CrossRefPubMed
37.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357. CrossRefPubMed Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357. CrossRefPubMed
38.
Zurück zum Zitat Schafer HH, De Villiers JN, Sudano I, et al. Recommendations for the treatment of hypertension in the elderly and very elderly ‒ a scotoma within international guidelines. Swiss Med Wkly. 2012;142:w13574. PubMed Schafer HH, De Villiers JN, Sudano I, et al. Recommendations for the treatment of hypertension in the elderly and very elderly ‒ a scotoma within international guidelines. Swiss Med Wkly. 2012;142:w13574. PubMed
39.
Zurück zum Zitat Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. CrossRef Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. CrossRef
40.
Zurück zum Zitat Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30. CrossRefPubMed Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30. CrossRefPubMed
41.
Zurück zum Zitat Forman D, Wenger NK. What do the recent American Heart Association/American College of Cardiology Foundation Clinical Practice Guidelines tell us about the evolving management of coronary heart disease in older adults? J Geriatr Cardiol. 2013;10:123–8. PubMedPubMedCentral Forman D, Wenger NK. What do the recent American Heart Association/American College of Cardiology Foundation Clinical Practice Guidelines tell us about the evolving management of coronary heart disease in older adults? J Geriatr Cardiol. 2013;10:123–8. PubMedPubMedCentral
42.
Zurück zum Zitat Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–84. CrossRefPubMed Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–84. CrossRefPubMed
43.
44.
Zurück zum Zitat Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366:1279–89. CrossRefPubMed Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366:1279–89. CrossRefPubMed
45.
Zurück zum Zitat Stafford S, Elahi D, Meneilly GS. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2011;59:1148–9. CrossRefPubMed Stafford S, Elahi D, Meneilly GS. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2011;59:1148–9. CrossRefPubMed
46.
Zurück zum Zitat Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:1049–58. CrossRefPubMed Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:1049–58. CrossRefPubMed
47.
Zurück zum Zitat Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8:405–18. CrossRefPubMed Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8:405–18. CrossRefPubMed
48.
Zurück zum Zitat Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57:2011–9. CrossRefPubMed Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57:2011–9. CrossRefPubMed
49.
Zurück zum Zitat DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315–7. CrossRefPubMedPubMedCentral DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315–7. CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012;14:304–14. CrossRefPubMedPubMedCentral Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012;14:304–14. CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13:939–46. CrossRefPubMed Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13:939–46. CrossRefPubMed
52.
Zurück zum Zitat Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705. CrossRefPubMed Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705. CrossRefPubMed
53.
Zurück zum Zitat Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502. CrossRefPubMed Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502. CrossRefPubMed
54.
Zurück zum Zitat Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–7. CrossRefPubMed Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–7. CrossRefPubMed
55.
Zurück zum Zitat Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. CrossRefPubMed Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. CrossRefPubMed
56.
Zurück zum Zitat Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–66. CrossRefPubMed Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–66. CrossRefPubMed
57.
Zurück zum Zitat Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479–84. CrossRefPubMed Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479–84. CrossRefPubMed
58.
Zurück zum Zitat Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–8. CrossRefPubMed Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–8. CrossRefPubMed
59.
Zurück zum Zitat Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109–19. CrossRefPubMed Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109–19. CrossRefPubMed
60.
Zurück zum Zitat Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50. CrossRefPubMed Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50. CrossRefPubMed
61.
Zurück zum Zitat Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–15. CrossRefPubMedPubMedCentral Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–15. CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74. CrossRefPubMed Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74. CrossRefPubMed
63.
Zurück zum Zitat Braun AK, Kubiak T, Kuntsche J, et al. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus ‒ a prospective randomised controlled multi-centre trial. Age Ageing. 2009;38:390–6. CrossRefPubMedPubMedCentral Braun AK, Kubiak T, Kuntsche J, et al. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus ‒ a prospective randomised controlled multi-centre trial. Age Ageing. 2009;38:390–6. CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Scherbaum WA, Kerner W, Hader C, Gräf-Gruss R. Für die DGG/ÖGGG „Praxis-Leitlinie: Diabetes im Alter.“ Eur J Geriatr. 2006;8:231–5. Scherbaum WA, Kerner W, Hader C, Gräf-Gruss R. Für die DGG/ÖGGG „Praxis-Leitlinie: Diabetes im Alter.“ Eur J Geriatr. 2006;8:231–5.
65.
Zurück zum Zitat Zeyfang A. [Practical aspects of diabetes care in the elderly]. MMW Fortschr Med. 2009;151:40–2. PubMed Zeyfang A. [Practical aspects of diabetes care in the elderly]. MMW Fortschr Med. 2009;151:40–2. PubMed
66.
Zurück zum Zitat Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13:497–502. CrossRefPubMed Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13:497–502. CrossRefPubMed
67.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes ‒ 2015: summary of revisions. Diabetes Care. 2015;38 Suppl 1:S4. American Diabetes Association. Standards of medical care in diabetes ‒ 2015: summary of revisions. Diabetes Care. 2015;38 Suppl 1:S4.
68.
Zurück zum Zitat American Diabetes Association. (10) Older adults. Diabetes Care. 2015;38 Suppl 1:S67–9. CrossRef American Diabetes Association. (10) Older adults. Diabetes Care. 2015;38 Suppl 1:S67–9. CrossRef
69.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9. CrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9. CrossRefPubMed
Metadaten
Titel
Geriatrische Aspekte bei Diabetes mellitus
verfasst von
Joakim Huber
Michael Smeikal
Monika Lechleitner
Peter Fasching
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-016-0955-3

Weitere Artikel der Sonderheft 2/2016

Wiener klinische Wochenschrift 2/2016 Zur Ausgabe

leitlinien für die praxis

Gestationsdiabetes (GDM)

leitlinien für die praxis

Insulintherapie bei Diabetes mellitus